Developing Homogenous 3D Neural Cultures for High Throughput Screening

Brain region-specific spheroids help scientists find new compounds to treat opioid use disorder and more.

Written byNiki Spahich, PhD
| 3 min read
3D rendered spheroids floating on a blue background.
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Drug use disorders are increasing worldwide, with few individuals receiving treatment for these conditions.1 In particular, abuse of prescription opioids and the rise in popularity of the synthetic opioid fentanyl has led to an opioid crisis in North America.2

To battle this epidemic, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-term (HEAL) Initiative in 2018. As part of this effort, scientists at the NIH National Center for Advancing Translational Sciences (NCATS) led by Marc Ferrer and Emily Lee developed a new way to screen for opioid use disorder (OUD) treatments, which they described in a recent Communications Biology paper.3 “We were looking for [3D] models that we could repurpose for screening compounds to target this initiative,” said Lee. “We realized quickly that the existing models were not adaptable for high throughput screening.”

To quickly test tens of thousands of compounds, the researchers needed to measure hundreds of wells in minutes with a plate reader. They found that brain organoids, which grow from stem or progenitor cell populations and differentiate into complex clusters that recapitulate in vivo morphology, were too heterogenous and took too long to mature for use in their high throughput screens.

As an alternative, Lee and Ferrer’s team came up with an innovative way to make brain region-specific spheroids suitable for their needs. Spheroids are simple 3D cell clusters that mature in a matter of weeks. Previously, researchers developed neural spheroids similarly to how organoids are made—by allowing pluripotent cells to differentiate within wells, which creates heterogenous populations. The NCATS team instead formed prefrontal cortex (PFC)-like and ventral tegmental area (VTA)-like spheroids by mixing together already differentiated neural cells at ratios that mimic each brain region’s in vivo composition.

“One of the interesting and different things that they did was aggregating a discrete number of cells and defining that [population] from the get go,” said Madeline Andrews, a neuroscientist at Arizona State University who was not involved in this study. “It demonstrates a new and interesting approach to using stem cell-derived populations to get a slightly more mature kind of cell type faster.”

The researchers confirmed that their starting ratios stayed consistent as the spheroids matured. They developed a plate reader assay that used a fluorescent dye to track intracellular calcium oscillations, which indicate neuronal activity.4 To model OUD, the team grew their spheroids in 384-well plates and exposed them to an opioid receptor agonist over 10 days, which mimicked neuronal stimulation from drug use. The treatment lowered calcium activity in the PFC-like spheroids, which was reversed upon application of a drug used clinically to treat opioid overdoses. In the future, they could expose their spheroids to a collection of chemicals called a compound library to identify additional therapies for OUD.

The brain region-specific spheroid models also proved promising for studying neurodegenerative diseases. Lee and Ferrer’s team assembled PFC-like spheroids with GABAergic neurons that contained an Alzheimer’s disease (AD) risk allele. These spheroids exhibited defective calcium activity, which was reversed when treated with compounds used to improve cognition in patients with AD, including the clinically-approved drugs Memantine and Donepezil. “We're currently working on expanding to additional diseases, looking at things like epilepsy and amyotrophic lateral sclerosis,” Lee said.

The researchers also plan to automate the manual steps in the spheroid maturation process and develop a high throughput screening method for testing assembloids made from their spheroids, as the VTA and PFC regions interact.

“I think [this model] is going to expedite discovery and also the understanding of what these therapeutics can actually do,” said Andrews. “Anytime we can push the timeline a little bit faster, it helps science proceed more quickly.”

Related Topics

Meet the Author

  • Niki Spahich headshot

    Niki Spahich earned her PhD in genetics and genomics from Duke University, where she studied Haemophilus influenzae membrane proteins that contribute to respiratory infections. She later explored Staphylococcus aureus metabolism during her postdoctoral fellowship in the Department of Microbiology and Immunology at the University of North Carolina at Chapel Hill. Prior to joining The Scientist, Niki taught biology, microbiology, and genetics at various academic institutions. She also developed a passion for science communication in written, visual, and spoken forms, which led her to start Science Riot, a nonprofit dedicated to teaching scientists how to communicate to the public through the lens of comedy. Niki is currently the manager of The Scientist's Creative Services Team.

    View Full Profile
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Accelerating Recombinase Reprogramming with Machine Learning

Accelerating Recombinase Reprogramming with Machine Learning

Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo

Products

waters-logo

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

zymo-research-logo

Zymo Research Partners with Harvard University to Bring the BioFestival to Cambridge, Empowering World-class Research

10x-genomics-logo

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA